Drug Trial Radar · NCT06439771
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Apr 23, 2024
Primary completion
Jul 30, 2027
Study completion Jul 29, 2028
Sponsor
- Lead sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, open-label, phase 2 clinical study to evaluate the efficacy, safety and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR-positive, HER2-zero-expression or HER2-low-expression
Conditions
- Locally Advanced or Metastatic Breast Cancer
Interventions
YL202 should be intravenously infusedDrug
For each patient, YL202 should be intravenously infused over 60±10 min.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR assessed according to RECIST v1.1Time frame: By the end of trial date, approximately within 36 months
- Determination of the recommended dose of YL202 in the pivotal clinical studyTime frame: By the end of trial date, approximately within 36 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.